FDA Approves Oral Testosterone Replacement Therapy Tlando
The approval was based on data from a phase 3 study that evaluated the efficacy and safety of Tlando in 95 adult hypogonadal male patients.
The approval was based on data from a phase 3 study that evaluated the efficacy and safety of Tlando in 95 adult hypogonadal male patients.
Testosterone therapy in the absence of polycythemia was not associated with an increased risk for major adverse cardiovascular events or venous thromboembolism.
Risk for myocardial infarction or stroke lower with testosterone therapy among men with hypogonadism and other cardiovascular risk factors
Testosterone undecanoate therapy reduces NAFLD grade in obese men with functional hypogonadism and type 2 diabetes
Benefits include significant improvement in body composition measurements over 6 months.
Study reveals an approximately 2-fold increased odds of venous thromboembolism associated with testosterone therapy in men with or without hypogonadism
Testosterone only recommended for postmenopausal women with hypoactive sexual desire dysfunction
Beneficial effects for postmenopausal women, with preference for nonoral testosterone administration
New studies find no increase in biochemical recurrence risk following radical prostatectomy or radiation therapy associated with testosterone replacement therapy.
A study of American men showed that those who adhered to a low-fat diet were twice as likely as men consuming usual diets to have hypogonadism.